Anzeige
Meldung des Tages: Mit Graphen gegen jede Abwehr — Die Zukunft der Drohnen ist da

Roche Holding News

Aktie
WKN:  851311 ISIN:  CH0012032113 US-Symbol:  RHHBF Branche:  Pharmazeutika Land:  Schweiz
354,80 €
+5,60 €
+1,60%
30.04.26
Depot/Watchlist
Marktkapitalisierung *
250,27 Mrd. €
Streubesitz
17,13%
KGV
25,93
Dividende
10,22 EUR
Dividendenrendite
2,93%
Nachhaltigkeits-Score
60 %
Index-Zuordnung
-

Roche Holding News

30.10.25 - GlobeNewswire
Roche purchases shares in tender offer for 89bio, Inc
Basel, 30 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary Bluefin Merger Subsidiary, Inc., has accepted for payment ...
29.10.25 - GlobeNewswire
Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue
New dengue antigen test delivers high clinical sensitivity and specificity, as well as inclusivity for all four dengue virus serotypes, helps clinicians confidently distinguish dengue from ...
28.10.25 - GlobeNewswire
Positive phase III results for Roche’s Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome
Gazyva/Gazyvaro versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete remission at week 52  If approved, ...
23.10.25 - GlobeNewswire
Changes to the Roche Enlarged Corporate Executive Committee
Basel, 23 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Nina Schwab-​Hautzinger (1975) has been appointed Head of Group Communications and a ...
23.10.25 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised
Basel, 23 October 2025
23.10.25 - GlobeNewswire
[Ad-hoc-Mitteilung gemäss Art. 53] Roche setzt starkes Wachstum in den ersten neun Monaten 2025 fort: Verkäufe steigen um 7% (CER) – Gewinn­prognose für das Gesamtjahr erhöht
Basel, 23. Oktober 2025
20.10.25 - GlobeNewswire
Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo 1 IMvigor011 is the first global phase III study to read out ...
20.10.25 - GlobeNewswire
FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III REGENCY data 1,2 Gazyva/Gazyvaro is the only ...
18.10.25 - GlobeNewswire
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1 -mutated populations, respectively, in a post-CDK inhibitor setting, ...
17.10.25 - GlobeNewswire
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Vamikibart is the first non-​steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patients Vision improvements ...
17.10.25 - GlobeNewswire
CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis
Positive recommendation based on phase II NOBILITY and phase III REGENCY data showing Gazyva/Gazyvaro’s superiority over standard therapy alone 1,2 Gazyva/Gazyvaro is the ...
16.10.25 - GlobeNewswire
Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025
Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial analyses unlocks research previously out of reach for traditional short read ...
13.10.25 - GlobeNewswire
Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types
Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30 abstracts across more than 10 cancer types at the European ...
06.10.25 - GlobeNewswire
Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm(1) and launches new comprehensive chronic kidney disease (CKD) algorithm panel
Roche, in collaboration with KlinRisk, Inc, has received CE-mark for the first AI-based risk stratification tool for assessment of progressive decline in kidney function. This tool will be ...
03.10.25 - GlobeNewswire
FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study 1 First and only combination therapy for the first-​line ...
03.10.25 - GlobeNewswire
Change in the Roche Board of Directors
Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Dr. Claudia Süssmuth Dyckerhoff has decided not to stand for re-​election as a member of the ...
01.10.25 - GlobeNewswire
Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash
Basel, 1 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of 89bio, ...
30.09.25 - GlobeNewswire
Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks
Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy for faster and more reliable diagnosis in emergencies. The test helps clinicians quickly identify ...
24.09.25 - GlobeNewswire
Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025
OCREVUS subcutaneous maintains consistent benefit-​risk profile after two years New late-​breaking data confirms OCREVUS significantly reduces disability progression in adults ...
22.09.25 - GlobeNewswire
Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer
evERA met its co-​primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and  ESR1 -mutated populations in post-CDK inhibitor setting, compared ...

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »
Anzeige

Aktie im Fokus

Mit Graphen gegen jede Abwehr
Plaid Technologies
0,396 €
+7,03%
Plaid Technologies Chart
Die Zukunft der Drohnen ist da
Mehr zur Aktie »